Abstract The progression of colorectal cancer is commonly characterized by accumulation of genetic or epigenetic abnormalities, altering regulation of gene expression as well as normal protein structures and functions. Nonetheless, there are some questions that remain to be elucidated, such as the origin of cancer cells and populations of cells initiating and propagating tumor development. Currently, there are two rival theories describing the process of carcinogenesis. One is the stochastic model, arguing that any cell is capable of initiating and triggering the development of cancer. Meanwhile, the cancer stem cell model hypothesizes that only a small fraction of stem cells possesses cancer-promoting properties. Typically, colorectal cancer stem cells (CSCs) share the same molecular signaling profiles with normal stem cells or embryonic stem cells, such as Wnt, Notch, TGF-β, and Hedgehog. Nevertheless, CSCs differ from normal stem cells and the bulk of tumor cells in their tumorigenic potential and susceptibility to chemotherapeutic drugs. This may be a possible explanation of the high percentage of cancer recurrence in patients who underwent chemotherapeutic treatment and surgery. This review article focuses on the colorectal cancer stem cell biomarkers and the role of upregulated signaling pathways implicated in the initiation and progression of colorectal cancer.
Introduction
Colorectal cancer (CRC) is the third leading type of cancer with 1,361,000 newly recorded cases in 2012, accounting for more than 694,000 deaths worldwide [1] . It is one of the main causes of cancer-related deaths in the Western countries with the overall 5-year survival rates of 11 % for patients with metastatic disease [1] .
Currently, the mechanisms of tumorigenesis and the precise origin of CRC cells still remain mostly unclear. Today tumors are considered not only simply as Bbags packed with homogeneous malignant cells^but rather like hierarchically organized systems of different cell types including cancer, stromal, hematopoietic, endothelial, and infiltrating cells. These cell types can contribute to the tumor heterogeneity, influencing metabolic, physiological, and morphological changes, ultimately enhancing tumor growth, development, the probability of treatment failure, and tumor recurrence.
There are two major models describing the process of colorectal tumorigenesis, including the stochastic and cancer stem cell models. The Bstochastic model^argues that tumors are biologically heterogeneous and not organized into systems with all cells within the tumor having an equal potential to tumor growth and metastasis [2] . Any functional discrepancies in the model are explained by stochastic factors, whether intrinsic (e.g., fluctuations of transcription factors or proteins) or extrinsic (e.g., environmental signals, immune responses) factors, altering normal cell behavior. The cellular heterogeneity in this model is explained by the hierarchy of the cell class emanating at the apex, distinct from the rest of the hierarchy and possessing different self-renewal capacities.
The cancer stem cell (CSC) model, proposed by Cohnheim in 1875 [3] , is based on the idea that some cancer cells retain properties of embryonic cells. This theory suggests that different internal or external agents are able to cause DNA damage, and cells encompassing the damaged DNA could give rise to morphologically distinct tumor cell populations. Such populations share distinct biochemical, physiological, and genetic profiles on different stages of cancer progression. The modern perception of the theory arises from extensive studies of leukemia stem cells [4, 5] , where it was found that cancer cells produced by tumor stem cells are similar to differentiated cells generated by progenitor cells [6] . Later, prospective CSCs were isolated for breast [7] , brain [8] , colon [9] , head and neck [10] , pancreatic [11] , melanoma [12] , hepatic [13] , lung [14] , prostate [15] , and ovarian [16] tumors. In all cases, generated xenograft models provided evidences that CSC can be a common feature across different cancer types. In addition, the model claims that the cells within the tumor may vary by the cancer initiating and propagating potential, reflecting hierarchical organization similarities between tumorigenic and nontumorigenic tissues.
Besides morphological, physiological, and metabolic differences of CSCs from normal stem cells, they also differ in their susceptibility to some chemotherapeutic drugs [17] . In fact, the high percentage of cancer recurrence in patients underwent chemotherapeutic treatment and surgery might be explained by the presence of CSC. Nonetheless, significant progress has been achieved in the identification of potential colorectal cancer stem cell biomarkers identifying the stage of the disease development, patient risk groups, and the chances of recurrence and dissemination, alongside with those who likely do not respond to certain types of treatment. Therefore, this review focuses on the current state of colorectal cancer stem cell biomarkers (CRCSC) and the pathways involved in the development of colorectal cancer from the perspective of the cancer stem cell model. This may be important due to the lack of understanding of specific biomarkers of CRCSC. Table 1 summarizes the features of some cancer stem cell biomarkers, including their aliases, main functions, and clinical value.
General criteria and methods of CRCSC identification
In order to study the biology of CRCSC, firstly, they have to be identified and, secondly, their nature has to be confirmed. The identification of CRCSC to this day has been relying mostly on molecular markers (described below in details) used in fluorescence-activated cell sorting (FACS), fluorescent microscopy, and other types of experiments. The original experiments clearly demonstrated the existence of the cells with the characteristics of CSC in colorectal cancer and were done by two independent groups of researchers led by John Dick [18, 19] and Ruggero De Maria [20] [21] [22] .
It must be noted that CRCSC, as well as CSC from other organs and tissues, have to comply to certain criteria in order to be considered a CSC. The major criteria for CSC would be a possession of specific properties such as self-renewal, multilineage differentiation, as well as a tumorigenic potential. Self-renewal refers to the capability of the cell to produce one undifferentiated cell with the stem cell characteristics and another cell with the potential to give rise to differentiated lineage during cell division. The multilineage differentiation potential refers to the CSC ability to differentiate and give rise to several tissue cell types. For example, the intestinal crypt contains several cell types that include enterocytes, goblet cells, Paneth cells, and enteroendocrine cells. Therefore, the CRCSC should be able to produce cell types resembling the abovementioned cell types upon in vitro differentiation. The self-renewal and multilineage differentiation are two stemness parameters of the SC, while the tumorigenic potential is the parameter of the cancer cell, which in combination produces a CSC. Tumorigenic potential is another important feature of CRCSC, which is usually assessed by the ability of the cell to invade the tissue and produce a tumor upon transplantation. The assessment of the tumorigenic potential has been routinely done by injection of the studied cells to the severe combined immune-deficient mice. The experiments used to assess these parameters are described in details elsewhere, and they are out of scope of this review.
Identification of colorectal cancer stem cell biomarkers
CD24 is a mucin-like cell surface adhesion glycoprotein attached to the external side of the plasma membrane by a phosphatidylinositol anchor [23] . CD24 plays a role in cell proliferation and differentiation, expressed by a number of immune system cell types, including B lymphocytes [24] , where it positively regulates proliferation and maturation of activated T cells [25] and granulocytes [26] . It has been reported that the protein can also be implicated in the development of a number of cancer types as breast, ovarian, lung, gastric, and colorectal [23] . Recently, it has been revealed that CD24 is expressed in nearly 50-68 % of CRCSC [27] . The expression of CD24 positively correlates with various stages of adenocarcinoma development, their degree of differentiation, and lymph node metastasis [28] . However, no significant correlation between a shortened period of patient survival and the presence of the marker was detected [29] . Although there are some evidences of CD24 as a tumor biomarker, the role of the protein as a CRCSC marker is less convincing and has not been fully proven.
CD26 (DPP4 or ADCP2) is a 110-kDA cell surface glycoprotein receptor expressed on the surface of various cell populations, including activated T, B, NK cells, macrophages, epithelial cells, and endothelial cells [30] . CD26 is composed of the transmembrane region, cytoplasmic domain, and extracellular stretch with dipeptidyl peptidase activities [31] . Originally identified for CD4 + memory T cell population, [108] ; van der Gun et al. [109] the marker can also serve a role in the activation of T cells through the collagen receptor molecule and possibly have a role in thymic ontogeny [32] . Other possible substrate targets of the CD26 molecule include RANTES, a crucial regulator of monocyte chemotaxis and interferon-inducible chemokines [33] . Recent works have also indicated a potential role of CD26 in the mobilization and migration of hematopoietic stem cells (HSC) [34] . A number of studies have found that the biomarker expression may be altered in a range of malignancies such as hepatocellular carcinoma, melanoma cells, lung adenocarcinoma, ovarian carcinoma, hematologic malignancies, and prostate carcinoma [30] . However, only one study has indicated the potential role of CD26 in the pathophysiology of CRCSC [35] . CD29 (β1-integrin) is a member of the large integrin superfamily. The protein comprises a large extracellular domain, transmembrane stretch, and a small intracellular domain. Functions of CD29 include activation of cell proliferation, growth, survival, and migration processes [36] . In normal intestinal mucosal cells, the marker has been found in the lower third part of crypts, which include progenitor and stem cells [37] . The combination of CD24/CD29 markers, which are found only in a small subpopulation of primary CR cancers, have been proposed as one of the tumor-initiating factors promoting SC proliferation, anchorage-independent growth, migration, and metastasis probably through regulation of the tumor microenvironment [38] . However, during late stages of CRC progression, CD29 expression is usually decreased, which has been associated with worse overall disease outcomes [39] , and after calibrating the effect of the disease stage, was higher than in normal colon tissues [39] . Nevertheless, there are still some ambiguities about the correlation between CD29 expression and the size of stem cell populations, and its role in the prediction of malignancy outcomes [40] .
CD44 is a cell adhesion, transmembrane hyaluronic acid receptor glycoprotein and acts as a transducer of extracellular signals influencing downstream Wnt/Beta-catenin pathways [41] . CD44 is involved in homing and activation of lymphocytes, hematopoiesis, angiogenesis, cell adhesion, and migration mechanisms [42] . Recently, CD44 was found in a number of CSCs including breast, head and neck, non-small lung, and colon cells [43] . In vitro experiments showed higher clonogenicity and tumor colony forming potential of CD44 + cells compared to the knockdown cell lines [44] . Moreover, only CD44
+ , but not CD44
− , cells retain morphological characteristics of tumor cells from which they were derived; meanwhile, deletion or overexpression of CD44 in APC Min/ + mice reduced tumor initiation properties [45] . Thus, CD44 has been suggested as a potential co-CSC marker, since in xenograft, CD44 + /CD166 + cells have a higher tumorigenicity [119] potential compared to CD44 − /CD166 − cells possibly through the involvement in the activation of the tyrosine kinase receptor c-Met [46] . The combination of CD44 and CD54 has been proven to specifically identify rectal cancer cells [47] . Nonetheless, the role of CD44 regarding development of malignancies and metastases is still debatable. This explains that many cancer types typically express multiple CD44 splice variants [48] . The marker's prognostic relevance regarding survival of patients, lymph node size, and tumor grade progression is inconsistent and controversial, with further studies warranted to understand the suitability of the CD44 molecule as a CRCSC marker. Pentaspan-transmembrane cholesterol-interacting CD133 protein, also known as prominin-1, contains the extracellular N-terminus, intracellular C-terminus with two cysteine-rich loops, five tyrosine phosphorylation sites, and two stretches of N-terminus glycosylation sites [49] . CD133 was firstly discovered as a cell surface marker of several subsets of hematopoietic cells, intestine bottom crypt cells, and also bone marrow-derived endothelial progenitor cells [50] . Currently, CD133 has been described for a wide variety of cancer tissues as brain [51] , lung [52] , liver [53] , prostate [54] , and colon [55] . Several studies have also proved that the glycoprotein may act as a CRC stem cell marker [9, [56] [57] [58] demonstrating raised abilities of CD133 + enriched cell populations to engraft and initiate solid tumor formation in immunodeficient mice compared to unsorted CRC cell populations. This can be explained by hyperactivation of Wnt/Ras-Raf-Mek-Erk signaling pathways [59] . Further, expression of the SRp20 splicing factor, a newly identified target gene of the Wnt/β-catenin pathway [60] , suggested that the expression of CD133 and CXCR4 in the tumor microenvironment acts through the CXCR4SDF-1 paracrine axis and usually correlates with poor overall survival rates of patients diagnosed with stage 2 and 3 colorectal cancers.
According to Mohammadi et al. [61] , the share of CD133 + decreases through a non-dysplastic subset of sessile serrated adenoma-polyp-lesions (SSA/P/L) (premalignant CR lesions) to non-dysplastic serrated hyperplastic polyps (HP) and ultimately through the passage of CSC to dysplasia, adenomas, and then cancers, remaining constantly higher than in normal tissue cells [62] . This fact indicates that upregulation of CD133 expression more probably occurs during early stages of CRC progressions, contributing to the entire process of cancer expansion [63] . Other potential routes of CD133 + expression in CSC include epigenetical mechanisms proposed by Yi JM et al. [64] , who found that hypermethylation of the CD133 gene promoter in a CpG island may lead to the upregulation of CD133. A number of papers evidenced a high prognostic relevance of CD133 in the promotion of malignancies. Several studies stated that higher levels of CD133 expression usually correlate with worse prognostic outcomes [65, 66] , and it may associate with the 5-FU-based chemotherapy resistance. Furthermore, CD133 + cell populations are more resistant to conventional radiation therapy, explaining increased chances of CRC relapse and radiotherapy-related risks [67] . However, the usefulness of CD133 is still debatable, as CD133
− cell populations are also able to generate tumor development in immunedeficient mice [68] . This fact was explained by Feng et al. [69] suggesting that CD133 + SW620 and CD133−SW620 colon cancer cells can switch between the two subpopulations in the presence of environmental stress and hypoxia-inducible factors (HIFs). Particularly, the P5 promoter of the CD133 gene is regulated by HIF-1α and HIF-2α through one of two E-twenty six (ETS) binding sites in the human embryonic colon and kidney cancer cells [70] . All these findings suggest a pivotal role of CD133 in cancer initiating and progression processes supporting its potential role as a prognostic biomarker in CRCSC.
CD166 or activated leukocyte cell adhesion molecule (ALCAM) is a transmembrane protein with five extracellular immunoglobulin-like domains [71] . CD166 is present on the surface of T and B lymphocytes [71] , myeloid [72] , and mesenchymal stem cells [73] . Apart from hematopoietic cells, the presence of CD166 has also been reported for lung [74] , breast [75] , ovarian [76] , and prostate [77] cancers. In colonic epithelial cells, CD166 was observed at the base crypt and progenitor niche cells or CRCSC [78] . Further, when xenografted on immunodeficient CD44 + /CD166 + /EpCAM + mice [38] , the tumorigenicity potential of the cells increased compared to wild-type mice, suggesting some not well-characterized functions. In a group of 111 patients with CRC diagnosis [79] , CD166 expression correlates with a shortened period of survival. Furthermore, Lugli et al. [46] have demonstrated positive correlation between the lymph node metastasis, tumor size, the number of colon polyps, and worse clinical prognosis [47] . In contrast to these findings, Horst et al. [80] have not found any statistically significant association between CD166 markers and CRC outcomes. These evidences suggest that upregulation of CD44 and CD166 must have a role in colon polyps to carcinoma transition events; however, the exact role remains yet to be defined.
Aldehyde dehydrogenase (ALDH1) was detected as a CSC marker for lung, prostate, breast, and pancreatic cancers and in a number of myelomas and leukemias [81] . High levels of ALDH1 were reported for a number of stem cell populations of various lineages, including colon progenitor cells [82] . Functions of ALDH1 include catalysis and irreversible oxidation of aldehydes to their corresponding carboxylic acids [83] . Several groups recorded reduced survival time for ovarian cancer [83] . An increased expression of ALDH1 is associated with increasing stage of cancer development and for normal tissues for poorly differentiated tumors and for metastatic colon patients [40] . Recently, ALDH1 was also detected in malignant colonic stem cells [84, 85] . During progression from normal epithelium cells to adenomas in APC mice, expression of ALDH1 was detected further up towards the apex of the crypt [84] .
Bmi1 has also been reported as a stem cell biomarker, playing a crucial role in the maintenance and self-renewal processes of stem cells in several tissue types [86] [87] [88] , where Bmi acts as an epigenetic chromatin modifier of multiple target genes [89, 90] . As a component of the polycomb repressive complex (PRC1), Bmi1 is implicated in the stimulation E3 ubiquitin-protein ligase activity of RNF2/RING2 [91] . Usually, in the gastrointestinal tract, Bmi1-expressing cells are abundantly expressed in the distal part of the small intestine [92] . Through a lineage tracing mechanism and in situ hybridization, it has been shown that Bmi1-expressing cells could be found at +4 and +5 positions, possibly playing an essential role in the crypt architecture [93] . Moreover, the selective removal of Bmi1-expressing cells carried out by diphtheria toxin (DT) treatment results in the disruption of the normal crypt composition. The logical question that arises is whether Bmi1-expressing cells take part in compensation of the loss of Lgr5 positive cells. As it was hypothesized, the number of Bmi1-expressing cells increased three times than in controls upon removal of Lgr5-expressing cells [92] . Bmi-1 has also been reported playing a role in the behavior and functioning of several cancer stem cell types including lung [94] , mammary [95] , prostate [96] , glioma [97] , and medulloblastomas [98] . However, although the oncoprotein has been correlated with the development, expansion, and metastasis of colorectal cancer, usually resulting in poor clinical outcomes and survival rates [99] [100] [101] [102] , the biomarker has rarely been reported playing a role in CRCSC [102, 103] . For example, Kreso et al. [103] detected the expression of Bmi1 in the LS174T cell line, a well-characterized human colon adenocarcinoma line. Injection of Bmi1 knockdown cells into interleukin-2 receptor γc-deficient mice (NSG) and nonobese diabetic-severe combined immune-deficient mice (NOD-SCID) resulted in reduction of tumor initiation properties and sphere formation potential compared to control cells, possibly through the CDKN2A locus, encoding p16INK4a and p14ARF [104] . Functioning of CRCSC and CRC progression seems to be dependent on the functioning of the canonical Bmi1 signaling pathway [103] .
The epithelial cell adhesion molecule (EpCAM) is a transmembrane glycoprotein mediating epithelial specific intracellular adhesion, cell migration, proliferation, differentiation, and signaling [105, 106] . Expression of EpCAM was observed on epithelium-derived cell populations and a number of human cancer tissues including colon, normal colon progenitor cells, and cancer initiating cells from colon, pancreas, breast, and prostate carcinomas [9, 57, 107] + cell lines appears to have a higher proliferation and cell colony formation potential, as well as a higher resistance to drugs with less spontaneous rates of apoptosis compared to EpCAM − populations [109] .
EpCAM expression has also been found to be reversely correlated with the primary tumor grade and with higher expression rates observed for earlier events of cancer progression [46] . It has also been noted that decreased EpCAM expression was associated with the tumor invasion potential of a metastatic cell, infiltration of the invasive tumor margin, and the presence of lymph node metastasis. Similarly, Langan et al. [39] found that decreased EpCAM expression rates correlate with the lymph node stage (N0 vs. N1 vs. N2). These facts suggest EpCAM involvement in cellular signaling processes necessitates further investigation of the protein for better understanding of its clinical, prognostic, and therapeutic value. Leucine-rich repeat-containing G protein-coupled receptor 5 (Lgr5) is a member of GPCR class A orphan receptor proteins. The protein consists of a seven transmembrane and a leucine-rich extracellular stretch. Lgr5 has firstly been discovered in colon crypt base columnar progenitor cells harboring Wnt/β-catenin pathway enhancing mutations [110] . After that, the overexpression of Lgr5 was reported for esophageal carcinomas, ovarian carcinomas, and hepatocellular carcinomas and a number of stem cell lines including CRCSC [111] . The loss of Lgr5 expression may be a necessary prerequisite for upregulation of genes responsible for epithelial mesenchymal transition (EMT) [112] . Moreover, elevated expression of Lgr5 correlates with low expression of miR-200c and high expression of vimentin [112] , one of the EMT characteristics of tumors, resulting in increased cancer invasiveness and lymph node metastasis. In adenocarcinomas, expression of the protein is localized on peripheral regions, which may lead to the loss of Lgr5 + cell polarity and promote cell migrations and tumor-host interface (carcinoma in situ) [113] . In a recent investigation [114] , it has been shown that patients with simultaneous expression of stem cell genes including Lgr5 may lead to 10-fold elevated risks of colon cancer emergence compared to those with low levels. Further, Takahashi et al. [113] reported that overexpression of Lgr5 correlates with higher levels of lymph node metastasis and decreased rates of patient survival. These findings defined a crucial role of Lgr5 in CR carcinogenesis and may be a suitable marker of CSC.
Musashi-1 (Msi-1) is a RNA-binding protein that firstly has been discovered for neuronal stem cells, where it competes with elF4G translation initiating factor [115] of two messenger RNAs (mRNAs): p21/Waf1. Further, Battelli et al. [116] investigated the HEK293T cell line and mNumb, an agonist of the Notch receptor [117] . These mRNAs are implicated in cell proliferation and tumorigenesis [118] . Several authors have also linked Msi-1 to stem and tumor cell biology, identifying Msi-1 as an intestinal stem cell putative biomarker discovered on the LT97 adenoma-like cell line and in primary colon tumors [119] . Further, knockdown of Msi-1 in HCT116 adenocarcinoma xenografts resulted in impaired tumorinitiating activities and ultimately tumor growth [118, 119] . These data suggest that Musashi-1 might play an important role in CSC carcinogenesis and tumor progression. In CRCS C, Msi-1 is involved in the control of Bstemness^regulating Wnt/Notch pathways [120, 121] . However, apart from the presence of Msi-1 on CRCSC as a stem cell progenitor, the role of the protein was extensively studied only for the nervous system [122] and no preliminary data about the influence of Msi-1 can be concluded. Taken together, these facts indicate the importance of Msi-1 in the development of CRCSC, stipulating further investigations.
Colorectal cancer stem cell signaling pathways

Wnt signaling pathway
The Wnt (Wingless) signaling pathway is an evolutionary conservative pathway found in all metazoan animals [123] . This pathway regulates an impressive array of intracellular processes as cell proliferation and differentiation [124] , cell polarity and motility [125] , stem cell fate determination, and tissue renewal, particularly in intestinal crypt [126] . In contrast, dysregulation of the cascade has been reported to play a role in many epithelial malfunctions, including colon tumorigenesis through the canonical (Wnt/β-catenin dependent) or the non-canonical (Wnt/β-catenin independent) pathways [127] . The relation of the non-canonical pathway in CSC theory is not well characterized. It is considered, however, that it can antagonize β-catenin-dependent hyperactivation of the Wnt pathway, suggesting some anti-oncogenic activities [128] .
Meanwhile, in the canonical pathway, the activity of the Wnt cascade is regulated by the amount of unbound β-catenin in cytoplasm [129] . Generally, the level of cytoplasmic β-catenin is maintained through the ubiquitin-mediated proteosomal degradation of the multiprotein complex containing β-catenin, axin, adenomatous polyposis coli (APC), and glycogen synthase kinase-3β (GSK-3β) [130] . However, upon binding of Wnt to the low density lipoprotein receptor protein (LRP)/Frizzled complex, its downstream targets are phosphorylated, thereby abrogating GSK-3β activit i e s , w h i c h re s u lt s i n e n h a n c e d r a t e s of no nphosphorylated β-catenin accumulation in the cytoplasm [129] . Non-phosphorylated β-catenin translocates to the nucleus, where it binds to the T cell transcription factor (TCF) and lymphoid enhancer-binding factors (LEF), simultaneously recruiting transcriptional coactivators as p300, cAMP response element-binding protein (CREB), and other components of the machinery [131, 132] . This leads to the expression of genes responsible for cell fate, proliferation, stem cell maintenance, and embryogenesis including Axin2, c-MYC, and ASCL2 [130] .
In normal intestine cells, expression of Wnt is detected in the bottom crypt cells, which is essential for the maintenance of stem cell compartmentalization and ultimately organization and patterning of the intestinal tract [133] . For example, the blockade of Wnt cascades by overexpression of Dickkopf-1 (DKK1), a functional antagonist of Wnt, or deletion of TCF4 and its target proteins as EphB2 and B3 receptors, which are also responsible for positioning of stem and differentiated cells, results in the abnormal colon tissue structure [134] . Furthermore, disruption of other targets of the Wnt cascade as ASCL2 [130] , LGR5 [135] , and CD44 [136] , which are confined by the crypt bottom, results in hyperplasia and the loss of the stem cell compartments [137] . Similarly, EpCAM signaling mechanisms seem to be closely interconnected with Wnt signaling networks [138] . For example, proteolysis of EpCAM by preselin-2 and TACE molecules results in the release of EpICD, an intracellular domain of EpCAM. After translocation of EpICD into the nucleus, it associates and regulates transcription of Wnt target genes as β-catenin, FHL2, and Lef1 [139] . Some studies indicate that CD133 also can promote β-catenin signaling functions and therefore inhibition of cancer cell differentiation [140] . Activities of the Wnt pathway have been shown reciprocally regulated by Bmi signaling [141] . For instance, it has been shown that Bmi1 can suppress the DKK1 molecule, therefore leading to upregulation of the Wnt signaling pathway and transcription of target genes as c-Myc, Lgr5, CD44, and Bmi1 [141] . Further, hyperactivation of DKK1 can modulate ALDH-1 activities having some impacts on cancer cell survival mechanisms, possibly through the upregulation of JNK, RhoA, and MAPK mechanisms [142] .
Interestingly, mutations activating and stabilizing β-catenin or inactivating the APC gene result in the permanent activation of the Wnt transcriptional program even in the absence of any extracellular signal. Further, silencing of β-catenin using siRNA, usually leads to decreased colonosphere formation, an important feature in the process of tumorigenesis and serving as surrogates of tumors [41] . In contrast, hyperactivation of TCF/LEF and c-Myc increases the formation potential of colonospheres [134] . The described events are considered to be the major cause of malignant transformation present virtually in all CRC patients.
NOTCH signaling pathway
The NOTCH signaling pathway is a highly conservative system presented almost in all multicellular organisms. It has been revealed that the NOTCH signaling pathway is fundamental for determination of cell fate, hematopoiesis, embryogenesis, and colorectal epithelium maturation, as well as for the maintenance of the balance between cellular proliferation and differentiation, migration, apoptosis, adjacent cell to cell communication, and the development of immune cells [143] . In mammalian cells, the NOTCH signaling cascade is comprised of two structurally distinct families: Delta-like ligands (DLL1, 3, and 4) and four transmembrane Notch homologue receptors (1, 2, 3, 4) interacting with two different families of ligands: Delta-like ligands (DLLs) and Jagged ligands [144] , which results in the activation of a number of downstream target genes such Deltex, Hes-1, and asp21 [145, 146] . Activation of the NOTCH pathway incepts upon binding of the NOTCH ligands to NOTCH receptors located on affecter cells [147] . Once the ligand binds to a corresponding receptor, the NOTCH receptor undergoes conformational changes exposing the previously protected site to the proteolytic cleavage guided by γ-secretase and metalloprotease, releasing the Notch intracellular domain (NICD) from the NOTCH complex [148] . The released cytoplasmic NICD fragment undergoes nuclear translocation, where it forms a complex with MAML-1, p300/CBP, Myc, p21, and core-binding factor-1 (CBF-1), modulating activities of hairy enhancer of split Hes-1, 5, 6, 7, and Math1 [149] .
In normal intestinal cells, all components of the NOTCH signaling cascade are expressed in intestinal bottom crypts of various stages of development and differentiation [150] , where activities of NOTCH pathways are essential for the regulation of progenitor cell and goblet cell differentiation [151] . Nevertheless, several studies showed that the aberrant hyperactivation of Notch signaling components is significantly higher in cancer cells compared to normal colonic mucosa cells. Aberrantly expressed NOTCH pathways are observed in the pathogenesis of a number of cancer types as pancreatic cancer [152] , prostate cancer [153] , Ewing sarcoma [154] , cervical cancer [155] , and colon cancer [156] . In a study conducted by Reedijk and colleagues [156] , it has been shown that the expression of Jagged ligands, Notch1, and HES1 in cancer cells was comparable to or slightly higher than that in normal intestinal crypt cells. Another study conducted by Meng and colleagues [157] revealed a correlation between the expression of hes1, Notch1, and nicd genes with colon cancer progression. Moreover, overexpression of these genes is hypothesized to be involved in chemoresistance of CRCSC.
Overexpression of the Notch signaling cascade has been reported to be associated with poor malignancy prognosis and responses for medical treatment in solid tumors as breast tumors [156] . It has been shown that Notch signaling-induced ALDH1A1 deacetylation is associated with the aggressive metastatic cancer phenotype [158] . Notch activities can also be regulated by MSI-1 signaling, resulting in the promotion of cell survival and enhancement of cell proliferation [159] . Similarly, the blockade of the Notch pathway depletes CD133 positive cells inhibiting the growth and propagation of tumor cells [160] . However, it appears to be that upregulation of Notch is mainly associated with the development of primary CRC, rather than metastatic CRC, indicating that hyperactivation of NOTCH takes a place in early stages of CRC development and downregulated in advanced CRCs [161] . For example, it was demonstrated that elevated levels of Jagged1, Jagged2, DLL1, DLL3, DLL4, and Notch receptors are present in 75 % of all CRC tissues [149] . The Notch/ STAT3/p63/Jagged signaling-induced hyperactivation can also lead to the upregulation of mTOR/PI3K/AKT, EGF, MAML-1, cyclin D1, c-Myc pathways, Bcl-2, Bcl-XL, and IAP family members, as well as a nuclear NFkB factor, constitutively active in human CRC tissues [143] . All these factors contribute to uncontrolled cell proliferation, altered goblet cell differentiation, mucin formation, and tumor cell chemoresistance to chemotherapeutic agents. Interestingly, not all components of the Notch cascade are implicated in the development of CRC. It is found, for example, that the expression of Notch1 and Hes-1, but not Notch2, Jagged1, and DLL3, is associated with the grade of tumor progression and increases from normal colon cells to adenomatous polyps and metastatic colon cancers [149] . Notwithstanding this fact, Notch signaling does not always function as an oncogenic factor and can act as a tumor suppressor depending on the cellular context. For instance, KLF4 C2H2 zinc-fingercontaining transcription factor in haploinsufficient mice showed increased susceptibility of colon cancer development [162] assuming anticancer properties of some components of the Notch cascade.
TGF-β signaling pathway TGF-β is a superfamily which is comprised of more than 30 proteins, including activins, bone morphogenetic proteins (BMP), and inhibins [163] . The TGF-β signaling cascade, its components, and downstream target genes have been reported involved in cell proliferation, motility and migration, differentiation, cell adhesion, extracellular matrix composition, and apoptosis [164] . It is now clear that TGF-β is an inhibitor of the cell cycle and is expressed in normal epithelial, nodal, and immune cells, playing an essential role in tissue and organ homeostasis [165] . On the cellular level, the pathway is one of the most commonly altered cell signaling cascades found in various cancer types [166] . In addition, hyperactivation of the pathway promotes angiogenesis and immunosuppression, which may be important in the context of carcinogenesis, tumor invasion, and metastasis [167] .
The cascade initiates upon binding of TGF-β1 ligands to three types of TGF-β receptor isoforms (TGFB1, TGFB2, and TGFB3), inducing the assembly and autophosphorylation of the receptor-ligand heteromeric complex [168] . This leads to the recruitment and phosphorylation of receptor-regulated SMADs (Smad1, Smad2, Smad3, Smad5, and Smad8) [168] . Phosphorylated SMAD forms homo-oligomeric and hetero-oligomeric complexes with the SMAD co-mediators (Smad4 and Smad10) through β2SP and SARA adaptor molecules [169] . The complex is then translocated into the nucleus where it regulates transcriptional activities of the multiple target genes [168] . Alternatively, the TGF-βR complexes can be subjected to degradation upon binding of inhibitory SMADs (Smad6 and Smad7) and SMAD ubiquitinated regulatory factor (SMURF) [170] .
Constant proliferation and differentiation is one of the main properties of gastrointestinal epithelium cells. Therefore, mutations in stem cell populations most likely result in increased chances of tumorigenesis and exacerbate probabilities of additional mutation occurrence. Targeting these cell populations may provide a rationale for better strategies for treatment of patients with colon cancer. Some of the TGF targets are important cell checkpoint genes as p21 (CDKN1A), p27 (CDKN1B), and p15 (CDKN2B) [171] . Hyperactivation of these genes leads to cell cycle arrest [165] , as well as Myc suppression [172] . However, once p21Cip1 is released from the Myc suppression, it transactivates by the SMAD-FOXO complex [172] . In normal intestinal epithelium cells, TGF-β signaling serves as a tumor growth suppressor initiating apoptosis and inhibiting cell proliferation. The mechanism of TGF-β-mediated apoptosis includes activation of the deathassociated kinases (DAPk) and SHIP, inhibiting downstream targets of Akt signaling [173] . In addition, apart from the tumor suppression role, TGF-β signaling also plays a role in the conditioning of mucosa-resident cells [164] . Therefore, development of CRC requires suppression of the pathway in early stages of development. However, during late stages of advanced primary tumor development, TGF-β promotes colorectal cancer tumorigenesis and associates with increased chances of cancer recurrence, likelihood of tumor relapse, and poor chances of survival [164] . Recently, it has been demonstrated that CD166 (pos) cell lines may have a higher proliferative potential compared to CD166(neg) cell, probably through the loss of TGF-β suppressive activities [174] . Although it is still not clear how the inhibitory effects of the cascade are switched to cancer-promoting properties, is has been suggested that TGF-β is capable of activating SMADindependent pathways, as mTOR/Akt/PI3K, JNK, and MAPK signaling cascades [173, 175, 176] . Moreover, the tbr2 gene seems to be prone to microsatellite instabilities, replication errors, and frameshift mutations, fluctuating from 40 to 80 % of all CRC cases [177, 178] . Interestingly, reconstitution of the tbr gene functions showed reduced tumorigenicity in in vivo experiments [179] . Similarly, mice with homozygous deletion of the smad and β2SP genes (β2SP±/Smad4±) demonstrated increased chances of aggressive colonic adenoma development compared with the wildtype controls [180] [181] [182] .
Hedgehog pathway
The Hedgehog (Hh) signaling pathway is one of the key regulators of stem cell maintenance, polarity, migration, and differentiation during the embryonic development [183] . There are three homologues of Hh receptor: Desert Hedgehog (Dhh), Indian Hedgehog (Ihh), and Sonic Hedgehog (Shh) [184] . Currently, it has been demonstrated that deregulation of this pathway correlates with higher chances of tumor progression in a wide variety of tissues, including CRC [144] . Several studies have also indicated that hyperactivation of Hh may regulate cancer stem cell maintenance. The cascade starts from RASP-mediated acylation of the Hh N-terminus, which is then released through the transmembrane transporter Dispatched [185] . Association of the released Hh with Drosophila patched gene (Ptch1) stabilizes the receptor Smoothened (Smo), allowing it to internalize and to activate signaling cascades by impeding its localization to the primary cilium, instead of the plasma membrane resulting in the activation of the cubitus interruptus (Gli) gene family of zincfinger transcription factors [184] . There are three homologues of Gli proteins: Hh target genes are activated by Gli1, Gli2 serves as an activator and repressor, and Gli3 represses transcription of the target gene [184] . It seems that Hh signaling is dependent on the balance of the Gli proteins [186] . However, in CRC stem cells and primary human colon carcinoma cells, the Hh-Gli pathway seems to be overactivated, which affects cell proliferation, tumor growth, survival, and metastases of cancerous cells [187] . Interestingly, Hh signaling is also involved in the maintenance of CD44 + /CD24 −/low phenotype in CSCs, contributing to the development of invasive cancer forms [188] . Inhibition of Hh cascades by cyclopamine has been reported to inhibit epithelial-to-mesenchymal transition (EMT) and metastasis [189] , indicating the potential therapeutic value of Hh pathway for drug treatment.
Crosstalk between signaling pathways Aberrant activation of individual stem cell pathways in CSCs rarely operates in isolation, which potentially can have some effects on how stem cells respond to extracellular cues. A number of studies indicate that Notch can antagonize Wnt signaling in a Su(H)-independent manner [190] . For example, in the absence of Notch, cells with active of Delta or Su(H) molecules can compensate the loss of the Disheveled mediated Wnt signaling [191, 192] , which can lead to the development of tumors associated with high levels of β-catenin in the nucleus [193] . Similarly, mice with inhibition of the Wnt/β-catenin pathway demonstrated decreased levels of Jagged1 expression in ovarian carcinoma cells, suggesting some backward loop interactions between Notch and Wnt pathways [194] . In turn, the Wnt cascade can regulate Gli3 expression and control Shh/Gli patterning of the Hh pathway [195] . It is interesting that Hh signaling can also antagonize Wnt signaling in the colonic epithelial cell cascade through downregulation of the nuclear β-catenin/TCF4 complex [196] . Apart from interactions between the listed pathways, Notch signaling appears to be interconnected with cell proliferation and developmental pathways such as mTOR/PI3K/Akt and Raf/Ras/Erk/Mek pathways in a variety of cell types [197, 198] . In another study, it has been shown that stabilization of Ras molecules in APC mutated mice usually correlates with higher chances of colon cancer development and is controlled by aberrant Wnt or Hh activities [199] . Similarly, the cells with constitutively active mTOR also display elevated levels of Hes1 and NICD expression, probably through STAT3/ Jagged/p63 cascades [200] . Treatment of the cells with mTOR inhibitors resulted in decreased levels of both Notch and mTOR signaling [200] . Alternatively, TGF-β/ALK5 activities can also be regulated through the PI3K/Akt-mediated mechanisms [173, 201] . For example, it is known that PI3K/ Akt signaling can attenuate the TGF-β-mediated cycle arrest or apoptosis program in response to insulin, interleukins, and other factors, possibly through Smad molecules [173, 201] . TGF-b/BMP pathways are also reciprocally interconnected with Wnt signaling [202] . Downstream components of the pathway, Lef/β-catenin/Smad regulate activities of the shared genes in a synergistic manner. Some studies have suggested connections between p53 molecules and the Hh pathway [203] , displaying the complexity of signaling pathway interconnections. Overall, recent studies have indicated that tumor heterogeneity on the molecular level may be a result of the interplay between numerous pathways having an active role in the development of a unique cancer genotype.
Conclusion
The cancer stem cell model suggests that tumors usually evolve from a small population of cancer initiating cells through accumulation of genetic, epigenetic, and somatic alterations, responsible for carcinogenesis, tumor propagation, metastasis, and relapse. According to the model, tumors are composed of cell populations with cancer initiating potential intermixed with the bulk of tumor cells. Therefore, the development of different treatment strategies and therapeutic options to suppress the tumor growth and a possible relapse is very much in need. However, the elaboration of new strategies may be hindered by significant obstacles. First of all, it is the apparent lack of conventional colorectal CSC markers to identify CSC from the rest of the tumor cells. Although putative biomarkers have been determined for different CSC cell populations, it seems that CSCs undergo significant changes in the level of biomarker expression, making it difficult to precisely indicate CSCs on different stages of tumor development based on cell surface biomarkers. In this regard, the investigation focused on elucidation of cell signaling profiles in CSC may provide a possible explanation of spatial and temporal expression of specific cell surface biomarkers. However, investigations related to cell signaling in CSC are complicated by crosstalk between different cell signaling networks and cellular diversity associated with the stem cell development during embryogenesis and normal tissue renewal. This requires further investigations focused on the elaboration of new opportunities in the designing of novel, more effective treatment strategies.
